medigraphic.com
ISSN 1405-8790 (Impreso)

2012, Número 4

<< Anterior

Rev Mex Med Fis Rehab 2012; 24 (4)


Recomendaciones de Manejo Integral de la Espasticidad en Adultos

Idioma: Español
Referencias bibliográficas: 126
Paginas: 106-144
Archivo PDF: 442.86 Kb.


FRAGMENTO

Es un gran orgullo presentar la segunda edición del consenso sobre «Evaluación y Tratamiento de la Espasticidad», que fue sometido a una revisión completa para su actualización y expansión de su contenido. Este texto ha sido escrito y editado por un grupo selecto de especialistas nacionales reconocidos en el campo de la neurorrehabilitación que merecen nuestro reconocimiento por su labor. La intención de este talentoso grupo es que este texto proporcione acceso fácil y al día sobre la información más relevante que ha sido referenciada en la literatura científi ca reciente y de más impacto sobre el tema.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Davis TL, Brodsky MA, Carter VA, DiFazio M, Fishberg B, Lai EC et al. Consensus statement on the use of botulinum neurotoxin to treat spasticity in adults. P & T (USA). 2006;31(11):666-82.

  2. Esquenazi A, Novak I, Sheean G, Singer BJ, Ward AB. International consensus statement for the use of botulinum toxin treatment in adults and children with neurological impairments: introduction. Eur J Neurol. 2010;17 Suppl 2:1-8.

  3. Montané E, Vallano A, Laporte JR. Oral antispastic drugs in nonprogressive neurologic diseases: a systematic review. Neurology. 2004;63:1357-63.

  4. Kita M, Goodkin DE. Drugs used to treat spasticity. Drugs. 2000;59(3):487-95.

  5. Ward AB, Aguilar M, De Beyl Z, Gedin S, Kanovsky P, Molteni F et al. Use of botulinum toxin type A in management of adult spasticity: A European consensus statement. Eura Medicophys. 2004;40(2):83-4.

  6. Ward AB, Wissel J, Molteni F, Yakovleff A, Gedin S, Aguilar M et al. European consensus statement on the use of botulinum toxin type A in the management of adult spasticity. Acta Neurol Belg. 2003;103(1):39.

  7. Aoki KR, Guyer B. Botulinum toxin type A and other botulinum toxin serotypes: a comparative review of biochemical and pharmacological actions. Eur J Neurol. 2001;8 Suppl 5:21-9.

  8. Aoki KR, Ranoux D, WiSSel J. Using translational medicine to understand clinical differences between botulinum toxin formulations. Eur J Neurol. 2006;13 Suppl 4:10-9.

  9. Brashear A. Clinical comparisons of botulinum neurotoxin formulations. Neurologist. 2008;14(5):289-98.

  10. Bula Botox - Brasil 2009.Available from: http://www.botox.eom.br/

  11. Bula Botox USA, 2008. Available from: http://www.botoxmedical.com/images/pdfs/BOTOX_prescribing_information.pdf

  12. Bula Dysport - Brasil2009. Available from: http://bulas.cxpass.net/index.pl?C=A&V=66506F737449443D37333931266163743D73686F7752656164436F6D6D656E7473

  13. Bula Dysport - UI< 2008. Available from: http://emc.medicines.org.hk/printfriendlydocument.aspx?documentid=870&companyid=68

  14. Bula Prosigne - Brasil 2008. Available from: http://www2.cristalia.com.br:8080/cristalia/mini_sites/prosigne/arquivos/bula.pdf

  15. Bula Prosigne - China 2008. Available from: http://www.btxa.com/product/Package%20insert.pdf

  16. Bula Xeomin - EMEA 2007. Available from: http://www.emea.europa.eu/pdfs/human/referrall xeomin/xeomin_annex%20I_lll_es.pdf

  17. Bula Neuronox - Coréia 2007 Available from: http://www.medy-tox.eo.kr/new_site/down/Neuronox_insert.pdf

  18. Bula Neurobloc - EMEA 2007. Available from: http://www.emea.europa.eu/humandocs/PDFs/EPAR/neurobloc/H-301-PI-es.pdf

  19. Cheng CM, Chen JS, Patel RP. Unlabeled uses of botulinum toxins: A review, part l. Am J Health Syst Pharm. 2006 15;63(2):145-52.

  20. Dressler D, Hallett M. lmmunological aspects of Botox, Dysport and Myobloc/NeuroBloc. Eur J Neurol. 2006;13 Suppl 1:11-5.

  21. Foster KA, Bigalke H, Aoki KR. Botulinum neurotoxin: from laboratory to bedside. Neurotox Res. 2006;9(2-3):133-40.

  22. FDA Appendix: Risk Evaluation and Mitigation Strategy (REMS) BLA STN 125360 Xeomin® (incobotulinumtoxin A). JULY 29, 2010 Available from: http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetylnformationforPatientsandProviders/UCM220886.pdf

  23. FDA information for Healthcare Professionals 08/2009: Onabotulinumtoxin A (marketed as Botox/Botox Cosmetic), Abobotulinumtoxin A (marketed as Dysport) and Rimabotulinumtoxin B (marketed as Myobloc) Available from: http://www.fda.gov/Drugs/DrugSafety/Postmarket­DrugSafetyinformationforPatientsandProviders/DrugSafetylnformationforHeathcareProfessionals/ucm174949.htm

  24. Klein AW, Carruthers A, Fagien S, Lowe NJ. Comparisons among botulinum toxins: an evidence-based review. Plast Reoonstr Surg. 2008;121(6):413e-422e.

  25. Lowe NJ. Overview of botulinum neurotoxins. J Cosmet Laser Ther. 2007;9(Suppl1):11-6.

  26. Naumann M, Jankovic J. Safety of botulinum toxin type A; a systematic review and meta-analysis. Curr Med Res Opin. 2004;20(7):981-90.

  27. Naumann M, Carruthers A, Carruthers J, Aurora SK, Zafonte R, Abu-Shakra S, et al. Meta­analysis of neutralizing antibody conversion with onabotulinumtoxin A (BOTOX®) across multiple indications. Mov Disord. 2010; 25(13):2211-8.

  28. Ney JP, Joseph KR. Neurologic uses of botulinum neurotoxin type A. Neuropsychiatr Dis Treat. 2007;3(6):785-98.

  29. Wenzel RG. Pharmacology of botulinum neurotoxin serotype A. Am J Health Syst Pharm. 2004;61(22 Suppl6):S5-10.

  30. Wenzel RG, Jones D, Borrego JA. Comparing two botulinum toxin type A formulations using manufacturers’ product summaries. J Clin Pharm Ther. 2007;32(4):387-402.

  31. Wenzel RG. Biosimilars: illustration of scientific issues in two examples. Am J Health Syst Pharm. 2008 Jul15;65(14 Suppl6):S9-15.

  32. Aoki KR, Guyer B. Botulinum toxin type A and other botulinum toxin serotypes: a comparative review of biochemical and pharmacological actions. Eur J Neurol. 2001;8 Suppl 5:21-9.

  33. Aoki KR, Ranoux D, Wissel J. Using translational medicine to understand clinical differences between botulinum toxin formulations. Eur J Neurol. 2006;13 Suppl 4:10-9.

  34. Brashear A. Clinical comparisons of botulinum neurotoxin formulations. Neurologist. 2008;14 (5):289-98.

  35. Dressler D, Hallett M. Immunological aspects of Botox, Dysport and Myobloc/NeuroBloc. Eur J Neurol. 2006;13 Suppl 1:11-5.

  36. FDA Appendix: Risk Evaluation and Mitigation Strategy (REMS) BLA STN 125360 Xeomin® (incobotulinumtoxin A). JULY 29, 2010 Available from: http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM220886.pdf

  37. FDA Information for Healthcare Professionals 08/2009: onabotulinumtoxin A (marketed as Botox/Botox Cosmetic), abobotulinumtoxin A (marketed as Dysport) and rimabotulinumtoxin B (marketed as Myobloc). Available from: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm174949.htm

  38. Foster KA, Bigalke H, Aoki KR. Botulinum neurotoxin from laboratory to bedside. Neurotox Res. 2006;9(2-3):133-40.

  39. Naumann M, Carruthers A, Carruthers J, Aurora SK, Zafonte R, Abu-Shakra S et al. Meta-analysis of neutralizing antibody conversion with onabotulinumtoxinA (BOTOX®) across multiple indications. Mov Disord. 2010; 25(13):2211-8.

  40. Wenzel RG. Biosimilars: illustration of scientific issues in two examples. Am J Health Syst Pharm. 2008;65(14 Suppl 6):S9-15.

  41. Brashear A, Gordon MF, Elovic E, Kassicieh VD, Marciniak C, Do M et al.; Botox Post-StrokeS-spasticity Study Group. Intramuscular injection of botulinumtoxin for the treatment of wrist and finger spasticity after astroke. N Engl J Med. 2002;347:395-400.

  42. Esquenazi A, Novak I, Sheean G, Singer BJ, Ward AB. International consensus statement for the use of botulinum toxin treatment in adults and children with neurological impairments--introduction. Eur J Neurol. 2010 Aug;17 Suppl 2:1-8.

  43. Lance JW. Symposium synopsis. In: Feldman RG, Young RR, Koella WP (eds). Spasticity: Disordered Motor Control. Chicago: Yearbook Medical Publishers, 1980.

  44. Olver J, Esquenazi A, Fung VSC, Singer BJ, Ward AB. Botulinum toxin assessment, intervention and aftercare for lower limb disorders of movement and muscle tone in adults: international consensus statement. Eur J Neurol. 2010;17 Suppl 2:57-73. (Toxina onabotulínica A en México).

  45. Wissel J, Ward AB, Erztgaard P, Bensmail D, Hecht MJ, Lejeune TM et al. European consensus table on the use of botulinum toxin type A in adult spasticity. J Rehabil Med. 2009;41(1):13-25.

  46. Brashear A, Mayer N. Dosing and administration of botulinum toxin for muscle overactivity in adults with an upper motor neuron syndrome. In: Brashear A, Mayer N (Editors). Spasticity and other forms of muscle overactivity in the upper motor neuron syndrome: etiology, evaluation, management, and the role of botulinum toxin. We move 2008. Available on: www.wemove.org

  47. Esquenazi A, Novak I, Sheean G, Singer BJ, Ward AB. International consensus statement for the use of botulinum toxin treatment in adults and children with neurological impairments--introduction. Eur J Neurol. 2010 Aug;17 Suppl 2:1-8.

  48. Francisco GE. Botulinum toxin: dosing and dilution. Am J Phys Med Rehabil. 2004;83(10 Suppl):S30-7.

  49. Olver J, Esquenazi A, Fung VSC, Singer BJ, Ward AB. Botulinum toxin assessment, intervention and aftercare for lower limb disorders of movement and muscle tone in adults: international consensus statement. Eur J Neurol. 2010;17 Suppl 2:57-73.

  50. Wissel J, Ward AB, Erztgaard P, Bensmail D, Hecht MJ, Lejeune TM et al. European consensus table on the use of botulinum toxin type A in adult spasticity. J Rehabil Med. 2009;41(1):13-25.

  51. Yablon SA. Botulinum neurotoxin intramuscular chemodenervation. Role in the management of spastic hypertonia and related motor disorders. Phys Med Rehabil Clin N Am. 2001;12(4):833-74.

  52. Mayer NH, Whyte J, Wannstedt G, Ellis CA. Comparative impact of 2 botulinum toxin injection techniques for elbow flexor hypertonia. Arch Phys Med Rehabil. 2008;89(5):982-7.

  53. Gracies JM, Lugassy M, Weisz DJ, Vecchio M, Flanagan S, Simpson DM. Botulinum toxin dilution and endplate targeting in spasticity: a double-blind controlled study. Arch Phys Med Rehabil. 2009;90(1):9-16.e2.

  54. Ward A, Roberts G, Warner J et al. Cost-effectiveness of botulinum toxin type A in the treatment of post-stroke spasticity. J Rehabil Med 2005; 37: 252-257

  55. Esquenazi A. Improvements in healthcare and cost benefits associated with botulinum toxin treatment of spasticity and muscle overactivity. European Journal of Neurology 2006, 13(suppl 4): 27-34.

  56. Brashear A, Gordon M, Elovic E et al. Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after stroke. N Engl J Med 2002;347(6): 395-400.

  57. Naumann M, Jankovic J. Safety of botulinum toxin type A: a systematic review and meta-analysis. Curr Med Res Opin. 2004;20(7): 981-90.

  58. Olver J, Esquenazi A, Fung V et al. Botulinum toxin assessment, intervention and aftercare for lower limb disorders of movement and muscle tone in adults: International consensus statement. European Journal of Neurology 2010;17(suppl. 2):57-73.

  59. Kaji R, Osako Y, Suyama K et al. Botulinum toxin type A in post-stroke lower limb spasticity: a multicenter, double blind, placebo-controlled trial. J Neurol. 2010;257:1330-1337.

  60. Wissel J, Schelosky L, Scott J et al. Early development of spasticity following stroke: a prospective, observational trial. J Neurol 2020;257:1067-1072.

  61. Wissel J, Ward A, Erztgaard P et al. European Consensus table on the use of botulinum toxin type A in adult spasticity. J Rehabil Med 2009;41:13-25.

  62. Simon O, Yelnik P. Managing spasticity with drugs. Eur J Phys Rehabil Med 2010;46:401-410.

  63. Davis TL, Brodsky MA, Carter VA et al. Consensus statement on the use of botulinum neurotoxin to treat spasticity in adults. P & T (USA). 2006;31(11):666-82.

  64. Esquenazi A, Mayer N, Garreta R. Influence of botulinum toxin type A treatment of elbow flexor spasticity on hemiparetic gait. Am J Phys Med Rehabil. 2008;87(4):305-10.

  65. Goldstein EM. Spasticity management: an overview. J Child Neurol. 2001;16(1):16-23.

  66. Jankovic J, Esquenazi A, Fehlings D, Freitag F, Lang AM, Naumann M. Evidence-based review of patient-reported outcomes with botulinum toxin type A. Clin Neuropharmacol. 2004;27(5):234-44.

  67. Lianza S. Espasticidad. Conceitos atuais baseados en evidências científicas. 1st ed. São Paulo: Allergan; Sociedade Paulista de Medicina Física e Rehabilitación; 2004.

  68. Mayer NH, Esquenazi A. Muscle overactivity and movement dysfunction in the upper motoneuron syndrome. Phys Med Rehabil Clin N Am. 2003;14(4):855-83.

  69. Scholtes VA, Dallmeijer AJ, Knol DL, Speth LA, Maathuis CG, Jongerius PH et al. The combined effect of lower-limb multilevel botulinum toxin type a and comprehensive rehabilitation on mobility in children with cerebral palsy: a randomized clinical trial. Arch Phys Med Rehabil. 2006;87(12):1551-8.

  70. Sheean G. Neurophysiology of spasticity. In: Barnes MP, Johnson GR (Eds). Upper motor neurone syndrome and spasticity, clinical management and neurophysiology. Cambridge: Cambridge University Press; 2001:12-78.

  71. Boyd RN, Graham HK. Objective measurement of clinical findings in the use of botulinum toxin type A for the management of children with cerebral palsy. Eur J neurol. 1999;6(Suppl 4):S23-S35.

  72. Calderón-González R, Calderón-Sepúlveda RF. Tratamiento de la espasticidad en parálisis cerebral con toxina botulínica. Rev Neurol. 2002;34(1):52-9.

  73. Davis TL, Brodsky MA, Carter VA, DiFazio M, Fishberg B, Lai EC et al. Consensus statement on the use of botulinum neurotoxin to treat spasticity in adults. P & T (USA). 2006;31(11):666-82.

  74. Giné-Garriga M, Guerra M, Marí-Dell’Olmo M, Martin C, Unnithan VB. Sensitivity of a modified version of the ‘timed get up and go’ test to predict fall risk in the elderly: a pilot study. Arch Gerontol Geriatr. 2009;49(1):e60-6.

  75. Graham HK, Aoki KR, Autti-Rämö I et al. Recommendations for the use of botulinum toxin type A in the management of cerebral palsy. Gait Posture. 2000;11(1):67-79.

  76. Guide for the Uniform Data Set for Medical Rehabilitation. Version 4.0 (Adult FIM). State University of New York, Bufalo. UB Fundation Activities, Inc., 1993.

  77. Hamilton BB, Laughlin JA, Fiedler RC, Granger CV. Interrater reliability of the 7-level functional independence measure (FIM). Scand J Rehabil Med. 1994;26(3):115-9.

  78. Heinen F, Molenaers G, Fairhurst C, Carr LJ, Desloovere K, Valayer EC, et al. European consensus table 2006 on botulinum toxin for children with cerebral palsy. Eur J Paediatr Neurol. 2006;10(5-6):215-25.

  79. Ijzerman MJ, Nene AV. Feasibility of the physiological cost index as an outcome measure for the assessment of energy expenditure during walking. Arch Phys Med Rehabil. 2002;83(12):1777-82.

  80. Jacobs JM. Management options for the child with spastic cerebral palsy. Orthop Nurs. 2001;20(3):53-9.

  81. Keith RA, Granger CV, Hamilton BB, Sherwin FS. The functional independence measure: a new tool for rehabilitation. Adv Clin Rehabil. 1987;1:6-18.

  82. Kiresuk TJ, Smith A, Cardillo JE. Goal Attainment Scaling: application theory and measurement. 1st edition. Hilsdale, New Jersey: Lawrence Eribaum Associates, Inc; 1994.

  83. Lianza S. Espasticidad. Conceitos atuais baseados en evidências científicas. 1st ed. São Paulo: Allergan; Sociedade Paulista de Medicina Física e Rehabilitación; 2004.

  84. Martínez-Martín P, Fernández-Mayoralas G, Frades-Payo B et al. Validation of the functional independence scale. Gac Sanit. 2009;23(1):49-54.

  85. Mahoney FI, Barthel DW. Functional evaluation: the Barthel Index. Md State Med J. 1965;14:61-5.

  86. Molenaers G, Schörkhuber V, Fagard K, Van Campenhout A, De Cat J, Pauwels P et al. Long-term use of botulinum toxin type A in children with cerebral palsy: treatment consistency. Eur J Paediatr Neurol. 2009;13(5):421-9.

  87. Novak S, Johnson J, Greenwood R. Barthel revisited: making guidelines work. Clin Rehabil. 1996;10:128-34.

  88. O’Brien C. Management of spasticity associated with stroke. In: O’Brien C, Yablon S (eds). Management of spasticity with botulinum toxin. Littleton, CO: Postgraduate Institute for Medicine; 1995:1-33.

  89. Pascual-Pascual SI, Herrera-Galante A, Póo P, García-Aymerich V, Aguilar-Barberà M, Bori-Fortuny I et al. Guía terapéutica de la espasticidad infantil con toxina botulínica. Rev Neurol. 2007;44(5):303-9.

  90. Pierson SH. Outcome measures in spasticity management. In: Mayer NH, Simpson DM (eds). Spasticity: etiology, evaluation, management, and the role of botulinum toxin. New York, NY: WEMOVE; 2002:27-43.

  91. Riberto M, Miyazaki MH, Jorge Filho D, Sakamoto H, Battistella LR. Reprodutibilidade da versão brasileira da Medida de Independencia Funcional. Acta Fisiatr 2001;8(1):45-52.

  92. Riberto M, Myiazaki MH, Jucá SSH, Sakamoto H, Pinto PPN, Battistella LR. Validação da versão brasileira da Medida de Independencia Funcional. Acta Fisiatr 2004;11(2):72-6.

  93. Riberto M, Pinto PPN, Sakamoto H, Battistella LR. Independencia funcional de pacientes con lesión medular. Acta Fisiatr 2005;12(2):61-6.

  94. Richardson D, Sheean G, Werring D, Desai M, Edwards S, Greenwood R et al. Evaluating the role of botulinum toxin in the management of focal hypertonia in adults. J Neurol Neurosurg Psychiatry. 2000;69(4):499-506.

  95. Segovia LS, Ortiz OE. Evaluation of the functional performance of patients with severe cerebral palsy with the instrument WeeFIM in the CRIT State of Mexico. Rev Mex Med Fis Rehab 2005;17(2):54-9.

  96. Ward AB, Aguilar M, De Beyl Z, Gedin S, Kanovsky P, Molteni F et al. Use of botulinum toxin type A in management of adult spasticity: a European consensus statement. Eura Medicophys. 2004;40(2):83-4.

  97. Kiresuk TJ, Smith A, Cardillo JE. Goal Attainment Scaling: application theory and measurement. 1st edition. Hilsdale, New Jersey: Lawrence Eribaum Associates, Inc; 1994.

  98. Calderón-González R, Calderón-Sepúlveda RF. Tratamiento de la espasticidad en parálisis cerebral con toxina botulínica. Rev Neurol. 2002;34(1):52-9.

  99. Davis TL, Brodsky MA, Carter VA, DiFazio M, Fishberg B, Lai EC et al. Consensus statement on the use of botulinum neurotoxin to treat spasticity in adults. P & T (USA). 2006;31(11):666-82.

  100. Esquenazi A, Novak I, Sheean G, Singer BJ, Ward AB. International consensus statement for the use of botulinum toxin treatment in adults and children with neurological impairments: introduction. Eur J Neurol. 2010;17 Suppl 2:1-8.

  101. Garreta-Figuera R, CharlerVJ, Toresquebrada GA. Guía de la práctica clínica del tratamiento de la espasticidad con toxina botulínica. Rev Neurol. 2010;50(11):685-99.

  102. Giovannelli M, Borriello G, Castri P, Prosperini L, Pozzilli C. Early physiotherapy after injection of botulinum toxin increases the beneficial effects on spasticity in patients with multiple sclerosis. Clin Rehabil. 2007;21:331-37.

  103. Goldstein EM. Spasticity management: an overview. J Child Neurol. 2001;16(1):16-23.

  104. http://www.fda.gov/drugs/drugssafey/postmaketdrugsafetyinformationforpatientsandproviders

  105. http://128.241.192.41/es/chapter_umns.asp

  106. Jankovic J, Esquenazi A, Fehlings D, Freitag F, Lang AM, Naumann M. Evidence-based review of patient-reported outcomes with botulinum toxin type A. Clin Neuropharmacol. 2004;27(5): 234-44.

  107. Mayer NH, Esquenazi A. Muscle overactivity and movement dysfunction in the upper motoneuron syndrome. Phys Med Rehabil Clin N Am. 2003;14(4):855-83.

  108. Olver J, Esquenazi A, Fung VSC, Singer BJ, Ward AB. Botulinum toxin assessment, intervention and aftercare for lower limb disorders of movement and muscle tone in adults: international consensus statement. Eur J Neurol. 2010;17 Suppl 2:57-73.

  109. Sheean G, Lannin NA, Turner-Stokes L, Rawicki B, Snow BJ; Cerebral Palsy Institute. Botulinum toxin assessment, intervention and after-care for upper limb hypertonicity in adults: international consensus statement. Eur J Neurol. 2010;17 Suppl 2:74-93.

  110. Bakhtiary AH, Fatemy E. Does electrical stimulation reduce spasticity after stroke? A randomized controlled study. Clin Rehabil. 2008;22(5):418-25.

  111. Caimmi M. Using kinematic analysis to evaluate constraint-induced movement therapy in chronic stroke patients. Neurorehabilitation Neural Repair 2008;22(1):31-9.

  112. Calderón-González R, Calderón-Sepúlveda RF. Tratamiento de la espasticidad en parálisis cerebral con toxina botulínica. Rev Neurol. 2002;34(1):52-9.

  113. Coote S, Murphy B, Harwin W, Stokes E. The effect of the GENTLE/s robot-mediated therapy system on arm function after stroke. Clin Rehabil. 2008;22(5):395-405.

  114. clínica del tratamiento de la espasticidad con toxina botulínica. Rev Neurol. 2010;50(11):685-99.

  115. Giovannelli M, Borriello G, Castri P, Prosperini L, Pozzilli C. Early physiotherapy after injection of botulinum toxin increases the beneficial effects on spasticity in patients with multiple sclerosis. Clin Rehabil. 2007;21:331-37.

  116. Kowalczewski J, Gritsenko V, Ashworth N, Ellaway P, Prochazka A. Upper-extremity functional electric stimulation-assisted exercises on a workstation in the subacute phase of stroke recovery. Arch Phys Med Rehabil. 2007;88(7):833-9.

  117. Kwon S, Hartzema AG, Duncan PW, Min-Lai S. Disability measures in stroke: relationship among the Barthel Index, the Functional Independence Measure, and the Modified Rankin Scale. Stroke. 2004;35(4):918-23.

  118. Meythaler JM, Vogtle L, Brunner RC. A preliminary assessment of the benefits of the addition of botulinum toxin a to a conventional therapy program on the function of people with longstanding stroke. Arch Phys Med Rehabil. 2009;90(9):1453-61.

  119. Olver J, Esquenazi A, Fung VSC, Singer BJ, Ward AB. Botulinum toxin assessment, intervention and aftercare for lower limb disorders of movement and muscle tone in adults: international consensus statement. Eur J Neurol. 2010;17 Suppl 2:57-73.

  120. Pomeroy VM, King LM, Pollock A, Baily-Hallam A, Langhorne P. Electrostimulation for promoting recovery of movement or functional ability after stroke: systematic review and meta-analysis. Stroke. 2006;37:2441-2.

  121. Selzer ME, Zorowitz RD. Designing prospective, randomized, multicenter clinical trials of physical rehabilitation treatment modalities. Neurorehabil Neural Repair. 2003;17(3):135-6.

  122. Walker MF, Leonardi-Bee J, Bath P et al. Individual patient data meta-analysis of randomized controlled trials of community occupational therapy for stroke patients. Stroke. 2004;35(9):2226-32.

  123. Garreta-Figuera R, Charler VJ, Toresquebrada GA. Guía de la práctica clínica del tratamiento de la espasticidad con toxina botulínica. Rev Neurol. 2010;50(11):685-99.

  124. Guide for the Uniform Data Set for Medical Rehabilitation. Version 4.0 (Adult FIM). State University of New York, Bufalo. UB Fundation Activities, Inc., 1993.

  125. Pascual-Pascual SI, Herrera-Galante A, Póo P, García-Aymerich V, Aguilar-Barberà M, Bori-Fortuny I et al. Guía terapéutica de la espasticidad infantil con toxina botulínica. Rev Neurol. 2007;44(5):303-9.

  126. Pomeroy VM, King LM, Pollock A, Baily-Hallam A, Langhorne P. Electrostimulation for promoting recovery of movement or functional ability after stroke: systematic review and meta-analysis. Stroke. 2006;37:2441-2.




2020     |     www.medigraphic.com